GLAUKOS Corporation announced that it will be completing the study of iStent by December 2009.

iStent trabecular micro-bypass stent reduces intraocular pressure (IOP) in subjects with open-angle glaucoma or ocular hypertension and co-existing cataract. It is a well-tolerated, safe, and effective modality for lowering IOP in eyes with open-angle glaucoma refractory to prior medical therapy and/or surgery. The micro-bypass stent is designed to bypass the site of maximum aqueous outflow resistance. It has an outer trabecular meshwork, which transports aqueous to multiple collector channels to restore normal physiologic outflow without need for obtaining a conjunctival filtration bleb.

The purpose of this study is to evaluate the safety and efficacy of the iStent trabecular micro-bypass stent in reducing intraocular pressure (IOP) in subjects with open-angle glaucoma. This 61 patient, phase IV study is ongoing, but not recruiting participants. The official title of the study is “A Study of the Glaukos Trabecular Micro-Bypass Stent in Open Angle Glaucoma Subjects 1 Stent Versus 2 Stents”.